back home
30-11-2022 Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2 23-11-2022 Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting 11-12-2020 Pharming announces enrolment of first patient in US clinical trial for the treatment of COVID-19 with RUCONEST® 09-12-2020 Sanofi and Kiadis satisfy competition condition related to the tender offer 21-01-2020 Pharming receives EMA approval of new facility for expansion of RUCONEST® production 14-01-2020 Pharming announces the placement of €125 million senior unsecured convertible bonds due 2025 14-01-2020 Pharming announces the launch of an offering of approximately €125 million senior unsecured convertible bonds due 2025 07-01-2020 Polyganics Achieves CE Mark Certification for LIQOSEAL® 25-02-2019 Pharming announces abstract presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and sponsorship of the AAAAI Foundation Michael M. Frank, MD, FAAAI Lectureship 31-10-2017 BioGeneration Ventures Fund III reaches EUR 82 million in final close 23-10-2017 Pharming announces warrant exercises and conversions of its Ordinary Bonds into shares mostly through cashless exercise 18-10-2017 BioGeneration Venture’s portfolio company SurgVision acquired by Bracco Imaging 03-10-2017 Dutch Mellon Medical secures € 6 million for market introduction of major innovation in surgical suture technology: single-handed suturing using the Switch® 02-10-2017 Pharming announces positive data from paediatric clinical trial with RUCONEST® 26-09-2017 Pharming Group N.V. and HAEi International Patient Organization announce partnership with Inceptua Medicines Access for “HAEi Global Access Program” 26-07-2017 Pharming announces publication of RUCONEST® prophylactic data in The Lancet 21-07-2017 Pharming announces completion of its refinancing with a single US$100 million debt facility on improved commercial terms 12-07-2017 Agendia’s MammaPrint® Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data 06-07-2017 Agendia's MammaPrint® recommended by the 2017 St. Gallen International Breast Cancer Guidelines in significant update 03-04-2017 ENG EUR 12,8 miljoen nieuwe financiering voor biotechonderneming Cristal Therapeutics eng 14-03-2017 BioGeneration Ventures contributes to Cristal Therapeutics EUR 12.8 million Financing Round 13-02-2017 Europese Commissie breidt marketingvergunning RUCONEST® uit met zelfstandige toediening 08-12-2016 Pharming announces completion of acquisition of all North American commercialisation rights for RUCONEST® from Valeant 07-12-2016 Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform 07-12-2016 Polyganics announces Birmingham Hand Centre efficacy study of nerve conduit NEUROLAC® in finger surgery

Agendia’s MammaPrint® Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data

IRVINE, CA, USA and AMSTERDAM, the Netherlands, July 10 2017 / B3C newswire / -- Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the American Society of Clinical Oncology (ASCO®) has today published revised early-stage breast cancer guidelines in the Journal of Clinical Oncology, titled The Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early Stage Invasive Breast Cancer: American Society of Clinical Oncology Practice Guideline(1).

This focused update is dedicated exclusively to Agendia’s MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test and was triggered by the practice-changing data from the randomized, prospective, phase III MINDACT trial which was published in August 2016 (2).

In a significant update to the 2016 guidelines, the ASCO panel identified MammaPrint as currently the only genomic test to be considered to inform treatment decisions in women with estrogen receptor-positive or progesterone receptor-positive, HER2-negative breast cancer with lymph node negative, or one to three positive lymph nodes who are at a high clinical risk of recurrence. For these patients, MammaPrint is now recommended by the ASCO Guidelines to inform decisions on withholding adjuvant (post-surgery) systemic chemotherapy due to its ability to identify patients with a good prognosis with limited chemotherapy benefit.

This is the first time that ASCO has recommended a genomic test to inform treatment decisions in withholding chemotherapy for lymph node positive patients, for whom lymph node involvement often causes them to be classified at high clinical risk and requiring chemotherapy. It is noted that such patients “should be informed that a benefit of chemotherapy cannot be excluded, particularly in patients with greater than one involved lymph node.”

Dr William Audeh, Chief Medical Officer at Agendia said: “This is a significant update to the ASCO guideline and testament to the clinical utility of the MammaPrint test as demonstrated in the MINDACT trial. MammaPrint is the only breast cancer genomic test that has been validated in a truly clinically high risk (luminal B) cohort of patients, providing physicians and their patients with unique genomic information to help personalize how their treatment is managed. The ASCO panel stated that reduction of overtreatment is an important goal, and confirmed the utility of MammaPrint in achieving this.

“This is the second guideline update for MammaPrint in three weeks. Based on MINDACT, both ASCO and the St. Gallen panel have now endorsed this test for both lymph-node negative and lymph node positive patients. Indeed, each of the four guidelines which included a review of the published findings of this unique trial so far this year have added or expanded their recommendation of MammaPrint,” said Dr. Audeh.

Mark R. Straley, Chief Executive Officer at Agendia said: “I am very pleased to see MammaPrint recommended by the updated ASCO guidelines. This will enable a whole new group of lymph-node positive patients to benefit from genomic testing, and not have their complex treatment decisions based entirely on clinical factors alone. At Agendia we are dedicated to improving the quality of life for early-stage breast cancer patients. ASCO’s recommendation is a powerful force in helping to extend the benefits of MammaPrint to reach many more women.”

MammaPrint is currently the only genomic breast cancer risk-of-recurrence test backed by level 1A prospective, randomized evidence to support the de-escalation of chemotherapy in patients who are classified as clinically high risk.  As stated in the ASCO guidelines, “the reduction of overtreatment in patients with early-stage breast cancer is an important goal (…) such a reduction would likely have the greatest societal and individual impact in patients with ER/PgR–positive disease.”

The ASCO guidance on the use of biomarkers in early-stage breast cancer supports the position of the recently-published biennial 2017 St. Gallen International Breast Cancer Guidelines that there is “no role for gene testing in clinical pathological low risk cases” (3), which are mostly node-negative, lower grade and smaller tumors (high estrogen receptor-positive, grade 1-2 and less than or equal to 2 cm).

MammaPrint was recognized as being supported by the highest level of clinical evidence by both the German Gynecological Oncology Group (AGO) and the European Group on Tumor Markers (EGTM) in March 2017. The test is also recommended for use in other important oncology practice guidelines including those of the European Society for Medical Oncology (ESMO), and several national guidelines in Europe.

You can access The Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early Stage Invasive Breast Cancer: American Society of Clinical Oncology Practice Guideline from the Journal of Clinical Oncology here: http://ascopubs.org/doi/full/10.1200/JCO.2017.74.0472

The Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) trial (EORTC 10041/BIG 3-04) is an independent, prospective, randomized, phase III, controlled clinical trial that investigated the clinical utility of MammaPrint, when used in conjunction with standard clinical pathological criteria, for the selection of patients unlikely to benefit from adjuvant chemotherapy.

From 2007 to 2011, 6,693 women who had undergone surgery for early-stage breast cancer enrolled in the trial, across 112 centers in nine countries. The results were published in the prestigious New England Journal of Medicine in August 2016.

About MammaPrint
MammaPrint is an in vitro diagnostic test, performed in a central laboratory, using the gene expression profile of breast cancer tissue samples to assess a patients’ risk for distant metastasis. MammaPrint is cleared by the US FDA and carries the CE Mark which certifies that the test complies with the quality standards set by the European In Vitro Diagnostic Directive, enabling the use of the test in the European Union.  MammaPrint is indicated for use by physicians as a prognostic marker only, along with other clinical-pathological factors.  The test is not intended to determine the outcome of disease, nor to suggest or infer an individual patient’s response to therapy.

About Agendia
Agendia is a privately held, leading molecular diagnostics company that develops and markets genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome.  Our offerings include MammaPrint®, a 70-Gene Breast Cancer Risk-of-Recurrence test, and BluePrint®, a Molecular Subtyping Assay that provides deeper insight leading to more clinically actionable breast cancer biology.
In addition, Agendia has a pipeline of other genomic products in development.  The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology.

For more information on Agendia or the MammaPrint and BluePrint tests, you can visit Agendia’s patient site at www.KnowYourBreastCancer.com or the corporate site at www.agendia.com.

Follow Agendia, Inc. on Facebook, Twitter, or LinkedIn to keep up-to-date with the latest news.


Instinctif Partners
Daniel Gooch / Lynne Trowbridge
Tel: +44 (0) 20 7866 7905


1  Krop I, Ismaila N, Andre F et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. DOI: 10.1200/JCO.2017.74.0472 Journal of Clinical Oncology - published online before print July 10, 2017

2 Cardoso F, van’t Veer LJ, Bogaerts J et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375: 717-29.

3 Curigliano G, Burnstein H, Winer E et al. De-escalating and Escalating Treatments for Early Stage Breast Cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017 mdx308.

Science Park 400 Matrix II Building 1098 XH Amsterdam +31 (0)653816427

  • - Corporate Communications
  • - Healthcare PR
  • - Financial Communications
  • - Content Marketing
  • - Social Media and Online Communications